NCT01690598 - Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions

Ovarian Cancer

Interventions

DRUG

Veliparib

Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.

DRUG

Topotecan

2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².

Trial Locations (1)

Department of Oncology, Vejle Hospital, Vejle